The GLP-1 phenomenon has moved far beyond a healthcare story.
Originally developed for diabetes, GLP-1 medicines are increasingly being used for weight management, lifestyle and wellbeing goals. In parallel, their growing influence is raising important questions for consumer-facing businesses about how behaviours, spending and expectations could change.
Over two thirds of Consumer CEOs say they are adjusting their product portfolios to reflect changes in demand driven by health-related consumer shifts*. And there are other new questions being prompted that these leaders will need to address:
- What role might healthcare access, affordability, cultural norms, social media, seasonality and intermittent usage play in shaping future demand across markets, consumer segments and demographics?
- As healthcare, retail, pharmacy and digital health become increasingly interconnected, how might consumer journeys, access models, ecosystem partnerships and alliance-driven distribution models continue to evolve?
- As adoption increases and new products enter the market, what role might evolving regulation, transparency and scientific evidence play in shaping consumer trust, business risk, industry responses and competitive dynamics?
Essentially, for consumer, retail and leisure leaders, the main question should no longer be whether GLP-1s matter, but what they may mean for demand, growth, and value creation.
Explore these questions and others in our new report; GLP-1s: Fact, Fiction or Future?
*KPMG CEO Outlook 2026, survey of 120 Consumer, Retail and Leisure leaders